GGrantIndex
Sort

40,608 grants matching prostate cancer

Immunogenomic determinants of response and resistance to neoadjuvant anti-PD-1 in resectable NSCLC

$374,578
Kellie Nicole Smith · Johns Hopkins University · R37 · FY2022 · CA

Mechanisms by which histone methyltransferases regulate nuclear receptor activity and response to therapy in hormone-driven tumors.

$374,578
Eneda Toska · Johns Hopkins University · R01 · FY2025 · CA

Distributed knowledge-based platform for radiotherapy plan quality control

$374,577
James D Murphy · University Of California, San Diego · R01 · FY2022 · HS

Quality of Life in Prostate Cancer Project

$374,573
Christine Sheehan Brennan · Lsu Health Sciences Center · R15 · FY2010 · CA

Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells

$374,560
Benjamin Tycko · Hackensack University Medical Center · R33 · FY2019 · CA

Prostate Boundary Detection in Ultrasound Images

$374,519
Insightful Corporation · R44 · FY2002 · AG

Development and Validation of a Novel Biomarker Assay for Cancer Diagnostics

$374,500
Katri S Selander · Blondin Bioscience, Llc · R43 · FY2016 · TR

Development and Validation of a Novel Biomarker Assay for Cancer Diagnostics

$374,500
Katri S Selander · Blondin Bioscience, Llc · R43 · FY2015 · TR

Towards Understanding Prostate Cancer Heterogeneity

$374,488
Mark A. Rubin · Weill Medical Coll Of Cornell Univ · R01 · FY2015 · CA

Endocrine disruptors: AR regulation and prostate cancer

$374,471
Karen E Knudsen · Thomas Jefferson University · R01 · FY2009 · ES

Translating gene-calcium interactions to precision medicine for colorectal cancer

$374,455
Qi Dai · Vanderbilt University Medical Center · U01 · FY2019 · CA

Vitamin D in Prostate Cancer: Tumor Vasculature Effects

$374,453
Roswell Park Cancer Institute Corp · R01 · FY2004 · CA

Targeting androgen receptor nuclear localization in prostate cancer

$374,450
Zhou Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

Targeting androgen receptor nuclear localization in prostate cancer

$374,450
Zhou Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA

CD8+ T Cell-Mediated Immunotherapy of Autochthonous SV40 T Antigen-Induced Tumors

$374,436
Todd D Schell · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2011 · CA

CD8+ T Cell-Mediated Immunotherapy of Autochthonous SV40 T Antigen-Induced Tumors

$374,388
Todd D Schell · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2012 · CA

Programmable transdermal drug delivery

$374,384
Micah Yairi · Los Gatos Research · R44 · FY2010 · AR

Programmable transdermal drug delivery

$374,384
Manish Gupta · Los Gatos Research · R44 · FY2011 · AR

A Novel Lineage Specific Metastasis Suppressor Pathway in Lung Cancer

$374,383
Don X Nguyen · Yale University · R01 · FY2014 · CA

Role of JMJD1A modifications in castration resistance of prostate cancer

$374,346
Jianfei Qi · University Of Maryland Baltimore · R01 · FY2022 · CA

Preclinical analyses of advanced prostate cancer in genetically-engineered mice

$374,307
Cory Abate-Shen · Columbia University Health Sciences · R01 · FY2019 · CA

Small Molecule Activators of PP2A (SMAPs) for Prostate Cancer Therapy

$374,305
Goutham Narla · Case Western Reserve University · R01 · FY2017 · CA

Small Molecule Activators of PP2A (SMAPs) for Prostate Cancer Therapy

$374,305
Goutham Narla · Case Western Reserve University · R01 · FY2016 · CA

Project 1 High-order assembly of MegaTrans complexes for hormone-independent enhancer activation

$374,247
Zhijie "jason" Liu · University Of Texas Hlth Science Center · U54 · FY2019 · CA

Regulation of Metastatic Development by Heritable Variants in the Tumor Microenvironment

$374,245
Paula Jill Hurley · Johns Hopkins University · R01 · FY2018 · CA